GRFS News and Press, Grifols S.A. From 05/10/19

Rigel Pharmaceuticals (RIGL) recently reported their Q1 earnings and hosted a conference call to update investors on the TAVALISSE launch, as well as pipeline progress and the company's financials. Rigel reported $8.1M in net product sales from TAVALISSE, which was a 10% increase quarter...

BARCELONA, Spain , April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper...

HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville , Georgia. The 11,000 square foot state-of-the-art facility officially opened its doors for bu...

RALEIGH, N.C. , April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more th...

BARCELONA, Spain , April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing region...

BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 5, 2019 . Grifols' Annual R...

RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 1105 W Main Street, Russellville , Arkansas. The 15,000 square foot state-of-the-art facility officially opened its doors for business on M...

Deals and Financings Grifols (MCE: GRF, [[GRFS]]), a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS (SHZ: 002252), one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in its US subsidi...

BARCELONA, Spain , Feb. 21, 2019 /PRNewswire/ -- Grifols has earned the honor of 2019 Category Leader in IV Workflow Management in the 2019 Best in KLAS: Software & Services report for its PharmacyKeeper Verification product.  This marks the third consecutive y...

BARCELONA, Spain , Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qual...